ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers to Predict CRT Response in Patients With HF (BIOCRT) (BIOCRT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01949246
Recruitment Status : Unknown
Verified January 2015 by Jagmeet Singh, Massachusetts General Hospital.
Recruitment status was:  Recruiting
First Posted : September 24, 2013
Last Update Posted : January 30, 2015
Sponsor:
Information provided by (Responsible Party):
Jagmeet Singh, Massachusetts General Hospital

Brief Summary:

The prospective study aims:

  1. To determine the role and mechanism of biomarkers for prediction of response to CRT
  2. To determine the role of biomarkers and their effect on left ventricular remodeling in patients undergoing CRT.

Condition or disease
Heart Failure

Detailed Description:

Cardiac resynchronization therapy (CRT) with biventricular pacing has emerged as a novel treatment for congestive heart failure (CHF) not responsive to optimal drug therapy. CRT is associated with significant improvements in hemodynamics and functional status of patients with CHF. The physiologic effect of CRT is achieved via placing electrical leads in the right and left ventricular walls, and synchronizing ventricular contraction. Over time, this leads to ventricular wall reverse remodeling, and sustained improvements in left ventricular ejection fraction (EF).

Currently, the indications for CRT include end-stage heart failure class II-IV with an EF < 35%, and a QRS duration > 120ms. The QRS duration is used as an indicator of the degree of ventricular electromechanical dyssynchrony, however, a growing number of studies have postulated its inability to predict response to therapy. As a result, other measures of mechanical dyssynchrony are being sought to guide therapy. The vast majority of these studies have examined clinical, cardiac, electrocardiographic, and device-specific indices, however, a widely accepted predictor of response to CRT is lacking.

CRT results in electromechanical synchrony, leading to an improved ejection fraction, exercise tolerance, and reduction of symptoms. Although electrical re-synchronization and intra-procedural hemodynamic improvement are achieved after the device is implanted, the sustained clinical improvement is likely due to ventricular reverse remodeling. A major issue with CRT is that approximately a third of patients receiving devices do not achieve improved clinical or functional status, and fail to undergo changes in ventricular geometry, and ventricular remodeling. It remains unknown whether this is due to abnormalities in the factors involved in lead placement or procedural strategies, geometric remodeling, alterations in cardiac energy metabolism, supply of energy (i.e. coronary blood flow), or inappropriate/inadequate microvascular proliferation.

This study will evaluate a series of biochemical markers implicated in pathophysiology of heart failure, in predicting response to CRT with biventricular pacing.


Study Type : Observational
Estimated Enrollment : 496 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Analysis of Circulating Biomarkers in Predicting Response to Cardiac Resynchronization Therapy (CRT) With Biventricular Pacing in Patients With Congestive Heart Failure (BIOCRT)
Study Start Date : September 2007
Estimated Primary Completion Date : January 2016
Estimated Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Group/Cohort
CRT patients
Patients undergoing CRT device implantation
Healthy patients
Healthy controls



Primary Outcome Measures :
  1. MACE [ Time Frame: 2 years ]
    death, HF hospitalization, left ventricular assist device, heart transplant


Secondary Outcome Measures :
  1. CRT clinical response [ Time Frame: 6 months ]
    For the definition of a positive response to CRT, patients will be classified according to the HF Clinical Composite Score (CCS). Responders will be defined as those with improved CCS from baseline to 6 month follow-up. Those not meeting this criterion will be considered nonresponders. An outcome panel consisting of two cardiologists will determine the clinical response of each subject based on review of the medical record. If there is disagreement in the assessment of either baseline or follow-up CCS amongst the two cardiologists, a third cardiologist will adjudicate the case.


Biospecimen Retention:   Samples With DNA
Whole Blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Outpatient or inpatient heart failure patients scheduled for CRT implantation
Criteria

Inclusion Criteria:

  • Study participant with an approved indication for a CRT or CRT-D system.

    1. New York Heart Association (NYHA) Class II, III, or IV Heart Failure unresponsive to drug therapy.
    2. EF < 35%.
    3. QRS width > 120 ms.
  • Study participant receiving optimal medical therapy including ACE inhibitor or Angiotensin Receptor Blocker (ARB), Beta-Blocker, and Diuretic.
  • Study participants with a history of significant congestive decompensation events within the last 12 months.

Exclusion Criteria:

  • NYHA Class I Heart Failure.
  • Co morbidities (e.g., cancer), which may limit lifespan < 6 months.
  • Severe aortic stenosis (valve area < 1.0 cm2).
  • Study participants that received cardiac surgery or intervention (i.e. coronary artery bypass grafting (CABG), valve surgery, angioplasty, arthrectomy) within the preceding 90 days.
  • Study participants with moderate to severe chronic obstructive pulmonary disease (COPD), defined as needing chronic oxygen therapy or recent hospitalization (within 30 days) for COPD flare up.
  • Concurrent pregnancy.
  • Study participants with primary pulmonary hypertension.
  • Study participants on continuous or intermittent infusion therapy for heart failure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01949246


Contacts
Contact: Jagemeet P Singh, MD PHD 617-726-4662 jsingh@partners.org

Locations
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Jagmeet P Singh, MD PHD    617-726-4662    jsingh@partners.org   
Principal Investigator: Jagmeet P Singh, MD PHD         
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Jagmeet P Singh Massachussetts General Hospital
Principal Investigator: Quynh A Truong, MD MPH Weill Medical College of Cornell University

Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jagmeet Singh, Jagmeet P Singh, M.D. Ph.D., Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01949246     History of Changes
Other Study ID Numbers: 2007P001921
First Posted: September 24, 2013    Key Record Dates
Last Update Posted: January 30, 2015
Last Verified: January 2015

Keywords provided by Jagmeet Singh, Massachusetts General Hospital:
Biomarkers

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases